Preclina, a leading non-clinical CRO specializing in autoimmune diseases, supports global competitiveness by swiftly delivering top-quality evaluation results for biotechs and pharmaceutical companies under new drug development, securing their position in the explosively expanding market of the autoimmune disease therapeutics.

Arthritis Research

To facilitate the development of new drugs for rheumatoid arthritis, a prototype of chronic inflammatory disease, our scientists with over 20 years of expertise optimized the most reliable disease models. Preclina’s precise and highly reproducible test results have been recognized across diverse clients.

Fibrosis Research

Preclina has established a strong efficacy evaluation system for the development of next-generation fibrosis therapeutics that enables overcoming of the limitations of Nintedanib in the treatment of pulmonary fibrosis. Discover Preclina’s potent fibrosis model portfolio!

Inflammatory Skin Disease Research

Amid the emergence of prominent targeted antibody therapies, against inflammatory skin disorders, we offer full range disease model services encompassing from screening to confirmation.

Neurological Disorders

Try to verify the therapeutic efficacy of candidate compounds developed to address the unmet needs in the treatment of multiple sclerosis, where brain damage continues to progress despite attempts to suppress relapsing disorders. Experience our internally established, highly reproducible efficacy pharmacology models to confirm their therapeutic efficacy

Collagen Vascular Disease Research

Given the scarcity of clinically proven treatments, the field of lupus pharmacology demands focused drug development efforts. We are conducting efficacy assessments utilizing key lupus animal models to advance lupus therapeutic development.

Get in touch with us to find out more
about how we can support you and your research!